Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
Authors:
Open Access
- 1 May 2011
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 4, 43-58
Abstract
Lung cancer remains a leading cause of death globally, with the most frequent type, nonsmall cell lung cancer (NSCLC), having a 5-year survival rate of less than 20%. While platinum-based doublet chemotherapy is currently first-line therapy for advanced disease, it is associated with only modest clinical benefits at the cost of significant toxicities. In an effort to overcome these limitations, recent research has focused on targeted therapies, with recently approved agents targeting the epidermal growth factor receptor and vascular endothelial growth factor (VEGF) signaling pathways. However, these agents (gefitinib, erlotinib, and bevacizumab) provide antitumor activity for only a small proportion of patients, and patients whose tumors respond inevitably develop resistance to treatment. As angiogenesis is a crucial step in tumor growth and metastasis, antiangiogenic treatments might be expected to have antitumor activity. Important targets for the development of novel antiangiogenic therapies include VEGF, fibroblast growth factor, platelet-derived growth factor, and their receptors. It is hypothesized that targeting multiple angiogenic pathways may not only improve antitumor activity but also reduce the risk of resistance. Several novel agents, such as BIBF 1120, sorafenib, sunitinib, and cediranib have shown promising preliminary activity and tolerability in Phase II studies, and results of ongoing Phase III randomized studies will be necessary to establish the potential place of these new therapies in the management of individual patients with NSCLC.Keywords
This publication has 103 references indexed in Scilit:
- Small Molecule Inhibitors of the Neuropilin-1 Vascular Endothelial Growth Factor A (VEGF-A) InteractionJournal of Medicinal Chemistry, 2010
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBritish Journal of Cancer, 2009
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumoursBritish Journal of Cancer, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBritish Journal of Cancer, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993